# EvoPAR-Breast01 (NCT06380751)

> Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

No report yet. It can be ordered.

- Drugs tested: saruparib (AZD5305) plus camizestrant; camizestrant; saruparib (AZD5305)
- Indication: first-line BRCA1/BRCA2/PALB2-mutated HR-positive, HER2-negative advanced breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06380751
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Advanced Breast Cancer
- Interventions: Saruparib (AZD5305); Camizestrant; Abemaciclib; Ribociclib; Palbociclib; Fulvestrant; Letrozole; Anastrozole; Exemestane
- Enrollment: 788
- Primary outcome: Progression-Free Survival (Arm 1 vs arm 2)

## Indexed commentary on EvoPAR-Breast01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 4
- X threads: 4
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=evopar-breast01-nct06380751

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06380751", "email": "<work email>"}; the inbox owner confirms by the emailed link.